Debasish Roychowdhury

5.5k total citations · 2 hit papers
19 papers, 3.1k citations indexed

About

Debasish Roychowdhury is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Debasish Roychowdhury has authored 19 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in Debasish Roychowdhury's work include Lung Cancer Treatments and Mutations (5 papers), Gastric Cancer Management and Outcomes (4 papers) and Renal cell carcinoma treatment (2 papers). Debasish Roychowdhury is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Gastric Cancer Management and Outcomes (4 papers) and Renal cell carcinoma treatment (2 papers). Debasish Roychowdhury collaborates with scholars based in United States, South Korea and Taiwan. Debasish Roychowdhury's co-authors include John Wagstaff, Jozef Mardiak, Lauren McCann, Cora N. Sternberg, Eunsik Lee, Robert E. Hawkins, Alexander Kavina, Carlos H. Barrios, Pamela Salman and Oleg Gladkov and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer.

In The Last Decade

Debasish Roychowdhury

19 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

2010 1.9k citations Cora N. Sternberg, Ian D. Davis et al. Journal of Clinical Oncology profile →
Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer

2018 225 citations Yi‐Long Wu, James Chih‐Hsin Yang et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Debasish Roychowdhury United States	12	2.1k	1.5k	1.1k	876	472	19	3.1k
Chen Mei China	14	2.2k 1.0×	1.6k 1.1×	1.2k 1.1×	1.0k 1.2×	266 0.6×	62	3.0k
Norbert Hollaender Switzerland	15	2.5k 1.2×	2.4k 1.6×	1.0k 1.0×	1.3k 1.5×	403 0.9×	29	4.0k
Erhan Gökmen Türkiye	12	2.2k 1.1×	2.1k 1.4×	1.0k 1.0×	1.3k 1.5×	159 0.3×	56	3.4k
Marine Gross‐Goupil France	29	1.9k 0.9×	995 0.7×	1.4k 1.3×	664 0.8×	138 0.3×	175	2.9k
Janice Dutcher United States	9	2.6k 1.2×	2.4k 1.6×	1.1k 1.0×	1.4k 1.6×	117 0.2×	13	3.6k
Christian Scheffold United States	25	1.0k 0.5×	900 0.6×	1.0k 1.0×	431 0.5×	346 0.7×	75	2.3k
Zoran Kovačević Serbia	7	2.1k 1.0×	2.0k 1.4×	723 0.7×	1.1k 1.3×	102 0.2×	31	3.0k
David McDermott United States	3	2.3k 1.1×	2.2k 1.5×	807 0.8×	1.3k 1.5×	102 0.2×	3	3.2k
Gladys Urbanowitz United States	8	2.2k 1.1×	1.9k 1.3×	2.0k 1.9×	996 1.1×	129 0.3×	12	4.2k
Laura S. Wood United States	29	3.1k 1.5×	2.2k 1.5×	2.3k 2.2×	1.4k 1.6×	187 0.4×	99	4.9k

Countries citing papers authored by Debasish Roychowdhury

Since Specialization

Citations

This map shows the geographic impact of Debasish Roychowdhury's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Debasish Roychowdhury with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Debasish Roychowdhury more than expected).

Fields of papers citing papers by Debasish Roychowdhury

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Debasish Roychowdhury. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Debasish Roychowdhury. The network helps show where Debasish Roychowdhury may publish in the future.

Co-authorship network of co-authors of Debasish Roychowdhury

This figure shows the co-authorship network connecting the top 25 collaborators of Debasish Roychowdhury. A scholar is included among the top collaborators of Debasish Roychowdhury based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Debasish Roychowdhury. Debasish Roychowdhury is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Sternberg, Cora N., Jozef Mardiak, Cezary Szczylik, et al.. (2023). Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial. Journal of Clinical Oncology. 41(11). 1957–1964. 10 indexed citations

Paine, Robert, E. Scott Halstead, Jae‐Hyun Park, et al.. (2022). Inhaled Sargramostim (Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor) for COVID-19-Associated Acute Hypoxemia: Results of the Phase 2, Randomized, Open-Label Trial (iLeukPulm). Military Medicine. 188(7-8). e2629–e2638. 10 indexed citations

Pouliot, Mylène, et al.. (2020). Efficacy of delayed administration of sargramostim up to 120 hours post exposure in a nonhuman primate total body radiation model. International Journal of Radiation Biology. 97(sup1). S100–S116. 38 indexed citations

Gardner, Robert B., et al.. (2019). Boosting Abscopal Response to Radiotherapy with Sargramostim: A Review of Data and Ongoing Studies. Cureus. 11(3). e4276–e4276. 13 indexed citations

Wu, Yi‐Long, James Chih‐Hsin Yang, Dong‐Wan Kim, et al.. (2018). Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 36(14). 1405–1411. 225 indexed citations breakdown →

Goto, Kōichi, Dong‐Wan Kim, Shun Lü, et al.. (2017). Phase II study of Crizotinib in East Asian patients (pts) with ROS1+ advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 28. ix91–ix91. 1 indexed citations

Goto, Kōichi, James Chih‐Hsin Yang, Dong‐Wan Kim, et al.. (2016). Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 34(15_suppl). 9022–9022. 16 indexed citations

Bardia, Aditya, Maura N. Dickler, Ingrid A. Mayer, et al.. (2015). Abstract P1-13-01: Phase I study of ARN-810, a novel and potent oral selective estrogen receptor degrader, in postmenopausal women with metastatic estrogen receptor positive (ER+), HER2- breast cancer. Cancer Research. 75(9_Supplement). P1–13. 1 indexed citations

Sternberg, Cora N., Ian D. Davis, Jozef Mardiak, et al.. (2010). Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial. Journal of Clinical Oncology. 28(6). 1061–1068. 1940 indexed citations breakdown →

10.

Altorki, Nasser K., Maureen E. Lane, Thomas Bauer, et al.. (2010). Phase II Proof-of-Concept Study of Pazopanib Monotherapy in Treatment-Naive Patients With Stage I/II Resectable Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 28(19). 3131–3137. 104 indexed citations

11.

Bussel, James B., Drew Provan, Tahir Shamsi, et al.. (2009). Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. The Lancet. 373(9664). 641–648. 396 indexed citations

12.

Lowy, Andrew M., Irfan Firdaus, Debasish Roychowdhury, et al.. (2006). A Phase II Study of Sequential Neoadjuvant Gemcitabine and Paclitaxel, Radiation Therapy With Cisplatin and 5-Fluorouracil and Surgery in Locally Advanced Esophageal Carcinoma. American Journal of Clinical Oncology. 29(6). 555–561. 7 indexed citations

13.

Roychowdhury, Debasish & Michael Lahn. (2003). Antisense therapy directed to protein kinase C-alpha (affinitak, LY900003/ISIS 3521): Potential role in breast cancer. Seminars in Oncology. 30(2D). 30–33. 34 indexed citations

14.

Roychowdhury, Debasish, et al.. (2002). A Report on Serious Pulmonary Toxicity Associated with Gemcitabine-Based Therapy. Investigational New Drugs. 20(3). 311–315. 69 indexed citations

15.

Stadler, Walter M., Hans von der Maase, Debasish Roychowdhury, et al.. (2002). Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urologic Oncology Seminars and Original Investigations. 7(4). 153–157. 49 indexed citations

16.

Peterson, Patrick, et al.. (2001). Incidence of thrombocytopenia with gemcitabine-based therapy and influence of dosing and schedule. Anti-Cancer Drugs. 12(4). 383–385. 6 indexed citations

17.

Kelly, Karen, Laura Lovato, Paul A. Bunn, et al.. (2001). Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group.. PubMed. 7(8). 2325–9. 23 indexed citations

18.

Mira, Jose L., et al.. (1999). Multilobated Large B-Cell Lymphoma Diagnosed Cytologically. Acta Cytologica. 43(5). 847–852. 1 indexed citations

19.

Roychowdhury, Debasish, et al.. (1996). New prognostic factors in nasopharyngeal carcinoma: Tumor angiogenesis and C-erbB2 expression. Cancer. 77(8). 1419–1426. 113 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact